The Exiting the European Union Committee hears from Cambridge University, Deimos UK, Cancer Research UK and AstraZeneca on Brexit and science.
This evidence session is part of the Committee's overarching inquiry looking at the progress of the UK's negotiations on EU withdrawal. In this session, the Committee focuses on the implications of Brexit for the research and science sectors, such as the UK's continued involvement in EU-wide agencies and collaborative projects, access to research funding post-Brexit, and changes to the general regulatory environment.
This session is the latest in a series of visits the Committee has undertaken with the aim of hearing from individuals and organisations impacted by Brexit across the country. Past visits include Armagh and Boston.
Thursday 18 January, Cancer Research UK Cambridge Institute, Cambridge University
- Eilis Ferran, Pro-Vice Chancellor for Institutional International Relations, Cambridge University
- Professor Greg Hannon, Director, Cancer Research UK Cambridge Institute
- Michael Lawrence, Business Development Director, Deimos UK
- Andy Williams, Vice-President of Research & Development, MedImmune and Cambridge Transition Team Leader, AstraZeneca